Denali Therapeutics Inc. (DNLI) stock
DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.00−0.08 (-0.44%)
Close on Nov 17, 2026Market cap $2.88BP/E –Yield –
Denali Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Denali Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$542.70M. For fiscal 2025 it was -$555.34M. The highest annual figure on record is $62.72M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$555.34M | – |
| FY2024 | Dec 31, 2024 | -$487.34M | – |
| FY2023 | Dec 31, 2023 | -$196.70M | – |
| FY2022 | Dec 31, 2022 | -$340.74M | – |
| FY2021 | Dec 31, 2021 | -$295.75M | -571.6% |
| FY2020 | Dec 31, 2020 | $62.72M | – |
| FY2019 | Dec 31, 2019 | -$213.18M | – |
| FY2018 | Dec 31, 2018 | -$46.37M | – |
| FY2017 | Dec 31, 2017 | -$90.14M | – |
| FY2016 | Dec 31, 2016 | -$87.43M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$130.54M | – |
| Q1 FY2026 | Mar 31, 2026 | -$137.36M | – |
| Q4 FY2025 | Dec 31, 2025 | -$137.37M | – |
| Q3 FY2025 | Sep 30, 2025 | -$137.43M | – |
| Q2 FY2025 | Jun 30, 2025 | -$134.96M | – |
| Q1 FY2025 | Mar 31, 2025 | -$145.58M | – |
| Q4 FY2024 | Dec 31, 2024 | -$129.85M | – |
| Q3 FY2024 | Sep 30, 2024 | -$123.19M | – |
| Q2 FY2024 | Jun 30, 2024 | -$116.59M | -168.4% |
| Q1 FY2024 | Mar 31, 2024 | -$117.72M | – |
| Q4 FY2023 | Dec 31, 2023 | -$132.57M | – |
| Q3 FY2023 | Sep 30, 2023 | -$113.80M | – |
| Q2 FY2023 | Jun 30, 2023 | $170.48M | – |
| Q1 FY2023 | Mar 31, 2023 | -$120.82M | – |
| Q4 FY2022 | Dec 31, 2022 | -$105.34M | – |
| Q3 FY2022 | Sep 30, 2022 | -$107.49M | – |
| Q2 FY2022 | Jun 30, 2022 | -$61.42M | – |
| Q1 FY2022 | Mar 31, 2022 | -$66.50M | – |
| Q4 FY2021 | Dec 31, 2021 | -$77.12M | -131.6% |
| Q3 FY2021 | Sep 30, 2021 | -$85.59M | – |
| Q2 FY2021 | Jun 30, 2021 | -$61.82M | – |
| Q1 FY2021 | Mar 31, 2021 | -$71.22M | – |
| Q4 FY2020 | Dec 31, 2020 | $244.08M | – |
| Q3 FY2020 | Sep 30, 2020 | -$60.12M | – |
| Q2 FY2020 | Jun 30, 2020 | -$61.28M | – |
| Q1 FY2020 | Mar 31, 2020 | -$59.97M | – |
| Q4 FY2019 | Dec 31, 2019 | -$57.76M | -177.3% |
| Q3 FY2019 | Sep 30, 2019 | -$50.16M | – |
| Q2 FY2019 | Jun 30, 2019 | -$62.76M | – |
| Q1 FY2019 | Mar 31, 2019 | -$42.51M | – |
| Q4 FY2018 | Dec 31, 2018 | $74.72M | – |
| Q3 FY2018 | Sep 30, 2018 | -$37.96M | – |
| Q2 FY2018 | Jun 30, 2018 | -$57.38M | – |
| Q1 FY2018 | Mar 31, 2018 | -$25.75M | – |
| Q4 FY2017 | Dec 31, 2017 | -$23.54M | – |
| Q3 FY2017 | Sep 30, 2017 | -$22.29M | – |
| Q2 FY2017 | Jun 30, 2017 | -$22.57M | – |
| Q1 FY2017 | Mar 31, 2017 | -$21.74M | – |
See a number that looks wrong?